Mangoceuticals, Inc. reported a significant decline in financial performance for the third quarter of 2025, with revenues of $84,246, down from $133,368 in the same period last year. For the nine months ending September 30, 2025, total revenues were $361,661, compared to $510,626 for the same period in 2024. The decrease in revenue is attributed to challenges related to the transition from the company's original telemedicine platform to a new telehealth system. The company also experienced a net loss of $7,618,776 for the quarter, a substantial increase from the $1,999,694 loss reported in the prior year, primarily due to increased stock-based compensation expenses.
In terms of operational changes, Mangoceuticals has been actively restructuring its business model. The company completed a reverse stock split on October 16, 2024, at a ratio of 1-for-15, reducing its outstanding shares from approximately 35.5 million to about 2.4 million. This move was aimed at stabilizing the stock price and improving market perception. Additionally, the company has been focusing on expanding its product offerings in the men's wellness sector, including erectile dysfunction treatments and hair loss products, marketed under various brand names such as Mango, Grow, Mojo, and Slim.
Mangoceuticals has also made strategic moves to enhance its intellectual property portfolio. In April 2024, the company acquired patents related to respiratory illness prevention technology for $20 million, which is expected to support future product development. However, the company has faced challenges, including the rescission of a Master Distribution Agreement with Navy Wharf, which was intended to market a nutraceutical product for blood glucose management. This agreement was terminated in July 2025 without incurring material penalties.
As of September 30, 2025, Mangoceuticals reported total assets of $16.5 million and total liabilities of $804,275, resulting in a working capital deficit of $0.2 million. The company has indicated a need for additional funding to support ongoing operations and future growth initiatives. Management anticipates raising capital through equity and debt offerings, although there is no assurance that such financing will be available on favorable terms. The company is also exploring strategic alternatives, including potential mergers and acquisitions, to enhance shareholder value.
Looking ahead, Mangoceuticals plans to continue its focus on marketing and expanding its product lines while addressing operational challenges. The company is currently conducting Phase II clinical trials for its patented respiratory illness prevention technology, with results expected in the fourth quarter of 2025. The management remains optimistic about future growth but acknowledges the need for additional capital to sustain operations and execute its business strategy effectively.
About MANGOCEUTICALS, INC.
Mangoceuticals, Inc. develops and markets telehealth-based men's wellness products and pharmaceutical therapies, including treatments for erectile dysfunction, hair loss, hormone balance, and weight management. The company connects consumers with licensed healthcare providers via its platform, offering compounded and FDA-approved medications. It operates through a network of telemedicine providers, a related pharmacy, and a proprietary customer portal, focusing on personalized, subscription-based health solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.